|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Beyond pharmacogenetics, NAT1 is also relevant to breast cancer.
|
31358821 |
2019 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We conclude that <i>NAT1</i> expression is not directly regulated by E<sub>2</sub>, DHT, 3<i>β</i>-adiol, or dithiothreitol despite high <i>NAT1</i> and <i>ESR1</i> expression in luminal A breast cancer cells, suggesting that <i>ESR1</i>, <i>XBP1,</i> and <i>NAT1</i> expression may share a common transcriptional network arising from the luminal epithelium associated with better survival in breast cancer.
|
29339455 |
2018 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
To date, however, the exact mechanism by which NAT1 expression affects mitochondrial bioenergetics in breast cancer cells has not been described.
|
29964355 |
2018 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The relationships between gene expression, and between NAT1 activity and RNA expression in breast cancer cell lines were evaluated using non-parametric statistical analyses.
|
29901116 |
2018 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These findings suggest that human NAT1 could serve as a target for the prevention and/or treatment of breast cancer.
|
29315819 |
2018 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
NAT1 expression showed a trimodal distribution in breast cancer samples (n = 1980) but not in tumor tissue from ovarian, prostate, cervical or colorectal cancers.
|
29969986 |
2018 |
|
Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
WES in the family identified the partner and localizer of BRCA2 (PALB2) c.419delA truncating mutation carried by the proband, her father, and her paternal uncle (all affected with BC) and the N-acetyltransferase 1 (NAT1) c.97C>T nonsense mutation carried by the proband's maternal aunt.
|
27648926 |
2017 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A novel role for rat NAT2 in mammary cancer was discovered unrelated to carcinogen metabolism, suggesting a role for human NAT1 in breast cancer.
|
28359264 |
2017 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of the present study was to determine whether NAT1 is a bona fide target of miR-1290, and to investigate the impact of NAT1 on breast cancer prognosis.
|
25528056 |
2014 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Human NAT1-specific inhibitors may act in biomarker detection in breast cancer and in cancer therapy.
|
24467436 |
2014 |
|
Breast Carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Our findings showed that the methylation of the NAT1 gene was identified in 39 of the breast carcinomas (54.2%), 23 normal (76.7%) and 25 benign breast tissue samples (80.6%).
|
18288399 |
2008 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Arylamine N-acetyltransferase 1 expression in breast cancer cell lines: a potential marker in estrogen receptor-positive tumors.
|
17973251 |
2008 |
|
Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Genetic polymorphisms of NAT1 and NAT2 may be also a breast-cancer susceptibility factor among postmenopausal women with a high intake of well-done meat.
|
17010218 |
2006 |
|
Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Smoking did not influence breast cancer risk nor did genetic variations in NAT1, NAT2 or GSTM1 in combination with smoking.
|
16049806 |
2005 |
|
Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We studied whether polymorphisms in N-acetyltransferase 1 and 2 and Glutathione S-transferase M1 and T1 genes modify the association between meat consumption and breast cancer.
|
15090724 |
2004 |
|
Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Some carcinogens that initiate rat mammary cancer are substrates of human N-acetyltransferase 1 (NAT1) and variation in NAT1 activity due to environmental or genetic causes may influence human susceptibility to breast cancer.
|
15226672 |
2004 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CYP2A6, CYP2B6, FMO5 and NAT1 emerged as new putative ERalpha-responsive genes in human breast cancer.
|
15084249 |
2004 |
|
Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
These results suggest that genetic polymorphisms of NAT1 and NAT2 have no independent effect on breast cancer risk, but they modulate breast cancer risk in the presence of GSTM1 and GSTT1 null genotypes.
|
12860276 |
2003 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
NAT-1 overexpression in clinical breast cancers was confirmed at the mRNA level and immunohistochemical analysis of NAT-1 in 108 breast cancer donors demonstrated a strong association of NAT-1 staining with estrogen receptor-positive tumors.
|
14517345 |
2003 |
|
Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Neither NAT1 slow genotype, or GSTT1 null genotype, alone or in combination with smoking, affected breast cancer risk.
|
12835615 |
2003 |
|
Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
These data suggest that CYP1A1*4, NAT1 and NAT2 variants are involved in the susceptibility to breast carcinoma by modifying the impact of exogenous and/or endogenous exposures.
|
11291049 |
2001 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Unfortunately, the results of both studies of NAT1*11 are imprecise and lack sufficient statistical power to address fully the potential contribution of NAT1*11 to breast cancer.
|
10698485 |
2000 |
|
Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In multivariate analyses, we found a 30% [95% confidence interval (CI) = 0.8-1.9] elevated risk of breast cancer associated with the NAT1*10 allele and a nearly 4-fold (95% CI = 1.5-10.5) elevated risk associated with the NAT1*11 allele.
|
10090301 |
1999 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Neither N-acetyltransferase 1 (NAT1) nor N-acetyltransferase 2 (NAT2) genotype alone was associated with increased breast cancer risk.
|
9610785 |
1998 |